Studying Patients With Cystic Fibrosis and Other Pulmonary and Pancreatic Disorders
Cystic fibrosis is a disease that affects many parts of the body, particularly the lungs and pancreas. The main purpose of this study is to further understand the natural history, clinical presentation, and genetics of cystic fibrosis.
Patients with cystic fibrosis will be asked to participate in this study by undergoing standard medical tests and procedures. Patients will have a history taken and have a physical examination as well as blood tests, and a sweat test (a test for cystic fibrosis of the pancreas in which electrolytes are measured in collected sweat). Patients may also be asked to provide samples of urine, stool, and sputum for additional tests. More complicated procedures such as bronchoscopy or bronchoalveolar lavage may be required for diagnosis, treatment, or research purposes.
Patients will receive appropriate treatment with antibiotics, pancreatic enzymes, vitamins, physiotherapy, and other agents. Medications may be given by mouth or injected into a vein.
This study will provide patients with information on the prognosis of the disease as well as recommendations for management of cystic fibrosis. In addition this study will provide information to researchers which may be useful in other studies of cystic fibrosis.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Diagnosis and Treatment of Patients With Cystic Fibrosis and Other Disorders of the Respiratory System and Pancreas|
|Study Start Date:||February 18, 1987|
This is an omnibus protocol for studying patients with cystic fibrosis and other familial
pulmonary and pancreatic disorders. The main purpose of the study is to expand knowledge of the natural history, clinical manifestations (phenotypes) and the genetic variants (genotypes) of cystic fibrosis. A well-characterized population of patients with cystic fibrosis will be invited to provide appropriate specimens for laboratory research and to participate in clinical trials of therapeutic agents for cystic fibrosis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00001223
|Contact: Milica S Chernick, M.D.||(301) firstname.lastname@example.org|
|United States, Maryland|
|National Institutes of Health Clinical Center, 9000 Rockville Pike||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL) 800-411-1222 ext TTY8664111010 email@example.com|
|Principal Investigator:||Milica S Chernick, M.D.||National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|